[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skin-laxity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skin-laxity":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,42,65,98,128,154,182,209,235,268,295,323],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100643455","plla-lasynpro-injections-for-skin-laxity-treatment-100643455",false,"NCT07637188","PLLA-LASYNPRO™ Injections for Skin Laxity Treatment","Evaluation of Histological Outcomes Following Poly-L-lactic Acid (PLLA) LASYNPRO™ Injections for Skin Laxity Treatment in Patients Requiring Post Bariatric Surgery: A Proof-of-Concept Clinical Study","Juläine","Inclusion Criteria:\n\n* Male or female aged ≤ 60 years\n* Previous bariatric surgery (one anastomosis gastric bypass)\n* Stable weight for at least 6 months prior to baseline\n* Post-weight loss skin laxity and ptosis requiring surgery\n* ΔBMI ≥ 7 defined as the change in BMI from scheduled bariatric surgery to baseline\n* BMI ≤ 30\n* Pittsburgh scale rating ≥10\n* Ability to give written informed consent\n* Willing to participate in the study and attending the visits\n\nExclusion Criteria:\n\n* Skin infection or skin inflammation status\n* Acute or chronic skin disease\n* ΔBMI \\\u003C 7 defined as the change in BMI from scheduled bariatric surgery to baseline\n* BMI \\> 30\n* Male or female aged 60 \\> years\n* Pregnancy and lactating; if a female is of childbearing potential, she should have a negative pregnancy test and should use a highly effective method to avoid pregnancy for the duration of the trial\n* Any clinically significant findings, as determined by the investigator, from laboratory tests and individual patient's medical history, that may contraindicate post-bariatric surgery for the patient\n* History of allergies to any of the constituents of the product\n* Haemorrhagic disease or under anticoagulant therapy\n* Have a known history of or susceptibility to keloid formation or hypertrophic scarring\n* Immune deficiencies","ALL","18 Years","60 Years",{"count":21,"type":22},15,"ESTIMATED","INTERVENTIONAL",[25],"NA","This single-center, open-label, intra-subject controlled proof-of-concept clinical study will evaluate the histological and clinical effects of Poly-L-lactic Acid (PLLA) LASYNPRO™ (Juläine) injections for treatment of skin laxity in patients requiring post-bariatric surgery. Fifteen participants will be enrolled. Each participant will serve as his or her own control, with one thigh treated with PLLA LASYNPRO™ and the contralateral thigh left untreated.\n\nParticipants will receive 3 injections in the treated thigh over approximately 3 months, followed by planned post-bariatric plastic surgery at 3, 6, or 9 months after the last injection, depending on assigned group. During surgery, tissue samples from treated and untreated areas will be collected for histological evaluation. A follow-up visit will occur approximately 30 days after surgery.\n\nThe primary endpoint is comparison of collagen type I and collagen type III between treated and untreated areas. Secondary endpoints include histological comparison of elastic fibers, stromal cell populations, inflammatory biomarkers, cell proliferation markers, and assessment of stretch marks, as well as safety. An exploratory endpoint is assessment of post-operative scar healing.",[28],"Skin Laxity","RECRUITING","2026-06-05",{"date":32,"type":33},"2026-06-09","ACTUAL",{"date":35,"type":33},"2026-05-13",{"date":37,"type":22},"2027-08",{"name":39,"class":40},"Nordberg Medical Italy srl","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":41},"100496950","evaluation-of-fractional-ablative-laser-treatment-for-skin-conditions-100496950","NCT05750901","Evaluation of Fractional Ablative Laser Treatment for Skin Conditions","Pilot Evaluation of Fractional Ablative Laser Treatment for Skin Laxity and Tightening","Inclusion Criteria:\n\n1. Male or female subjects aged 18-85 years\n2. Fitzpatrick skin type I-VI\n3. Has visible skin laxity in the treatment region or has a scar\n4. Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study, and no plans to become pregnant for the duration of the study (Applicable to female subjects only)\n5. Willing to have digital imaging and measurements taken of the treatment area and agree to use for presentation, educational or marketing purposes\n6. Subject must be able to read, understand and sign Informed Consent Form in English\n7. Must be willing to adhere to the treatment and follow-up schedule and post-treatment care instructions\n\nExclusion Criteria:\n\n1. Participation in a clinical trial of another device or drug within 6 months prior to enrollment or during the study.\n2. Any type of prior cosmetic treatment to the target area at physicians' discretion\n3. History of malignant tumors in the target area.\n4. Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, large moles.\n5. Pregnant and\u002For breastfeeding (Applicable to females only)\n6. Having an infection, dermatitis or a rash in the treatment area.\n7. Significant concurrent illness, such as diabetes mellitus, cardiovascular disease, e.g., uncontrolled hypertension or pertinent neurological disorders.\n8. Suffering from coagulation disorders or taking prescription anticoagulation medications.\n9. History of keloid scarring, hypertrophic scarring or of abnormal wound healing.\n10. History of immunosuppression\u002Fimmune deficiency disorders or currently using immunosuppressive medications.\n11. History of vitiligo, eczema, or psoriasis.\n12. History of disease stimulated by heat, such as recurrent herpes simplex and\u002For herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.\n13. History of radiation to the treatment area or undergoing systemic chemotherapy for the treatment of cancer.\n14. Current smoker or history of smoking within 6 months of study participation.\n15. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study",true,"85 Years",{"count":52,"type":22},1000,[25],"Evaluate the safety and efficacy of the fractional ablative laser for treatment of skin laxity and tightening",[28],"2026-04-21",{"date":58,"type":33},"2026-04-23",{"date":60,"type":33},"2022-11-01",{"date":62,"type":22},"2027-12-30",{"name":64,"class":40},"Sciton",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100618517","prospective-clinical-investigation-to-evaluate-the-safety-and-effectiveness-of-juline-in-improving-gluteal-skin-laxity-in-adults-100618517","NCT07332650","Prospective Clinical Investigation to Evaluate the Safety and Effectiveness of Juläine™ in Improving Gluteal Skin Laxity in Adults.","A Pivotal, Open-Label, Two-Arm, Randomized, Parallel-Group, Prospective Clinical Investigation to Evaluate the Safety and Effectiveness of Juläine™ in Improving Gluteal Skin Laxity in Adults.","Inclusion Criteria:\n\n* Adults aged 18 to 55 years;\n* Body Mass Index (BMI) between 18.5 and 24.95 kg\u002Fm².\n* Skin laxity of the gluteal region defined as sagging and reduced tightness of the skin.\n* Women of childbearing potential must be willing to abide by the contraceptive requirements\n* Ability to understand the study and provide informed consent, attend follow-up visits, and follow post-injection instructions.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding, or planned pregnancy\u002Flack of adequate contraception (through 8 weeks post-study);\n* Is planning to donate\u002Fbank or retrieve eggs (ova, oocytes) or donate sperm during the study or within 8-weeks of the end of participation of the clinical investigation.\n* Active infection, inflammation or lesions at or near the treatment site.\n* Acute infection at screening;\n* History of autoimmune disease;\n* Immune deficiencies;\n* History of hypertrophic scarring or keloid formation;\n* Previous surgical procedures involving the buttocks\n* Aesthetic procedure on the buttocks (including fillers, elevation wires, radiofrequency, ultrasound, cryotherapy, fat injection, neurotoxin, laser or light treatment, or chemical peel) within 6 months prior to randomization.\n* Hemorrhagic disease or ongoing use of antiplatelets\u002Fanticoagulant therapy.\n* Treatment with chemotherapy, immunosuppressive agents, systemic corticosteroids within 3 months before treatment (inhaled or ophthalmic corticosteroids are allowed).\n* Use of hormonal replacement therapy (HRT) unless the participant has been on a stable dose for at least 3 months prior to screening and does not plan to make any changes to the HRT regimen during the study period.\n* Use of topical corticosteroids, topical prescription retinoids in the treatment area within 1 month of the Baseline visit or systemic retinoid treatment within 6 months of the baseline visit, or plan to receive such treatment.\n* Use of other agents that inhibit collagen production.\n* Known allergy or hypersensitivity to any component of the investigational product.\n* History of herpes simplex rashes, malignant skin diseases, or any other serious dermatologic or systemic disease.\n* Presence of any condition that may impair wound healing (e.g., connective tissue disorders, severe malnutrition).\n* Planned or ongoing cosmetic procedures involving the buttocks or surrounding area during the period of clinical investigation.\n* Extensive tattoos covering \\>50% of the total gluteal area.\n* Participants actively taking GLP-1 medications with the intention of achieving additional weight loss (expected \\>10% during study) will be excluded. Participants on a stable GLP-1 regimen (≥3 months) for diabetes management or weight maintenance, with documented weight stability (±10% in past 6 months) and no planned or expected weight change \\>10%, may be included.\n* Any other medical or psychological condition that, in the opinion of the investigator, may interfere with participation in clinical research or evaluation of results.","55 Years",{"count":74,"type":22},100,[25],"This study aims to evaluate the safety and effectiveness of Juläine™ (poly-L-lactic acid) injections for the treatment of buttock skin laxity.\n\nParticipants will be randomized to an immediate-treatment group or a delayed-treatment group. The immediate-treatment group will receive 2 to 3 treatment sessions over up to 2 months and will be compared with the delayed-treatment group during the control period; the delayed-treatment group will receive the same treatment after the delay.\n\nThe primary objective is to assess clinical improvement in buttock skin elasticity 6 months after the last treatment, defined as an increase in skin elasticity measured by a cutometer. Total study participation is up to 16 months, including follow-up.\n\nThis multicenter trial will be conducted in Brazil.",[78,28],"Skin Quality",[80,81,82,83,84,85,86,87],"Poly-L-lactic acid","PLLA","Aesthetic","Injectable filler","Buttocks","Gluteal skin laxity","Buttock skin laxity","Skin elasticity","NOT_YET_RECRUITING","2026-03-16",{"date":91,"type":33},"2026-03-19",{"date":93,"type":22},"2026-10",{"date":95,"type":22},"2027-06",{"name":97,"class":40},"Nordberg Medical AB",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":49,"sex":17,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100628507","phase-2-assess-efficacy-of-a-nanodiamond-periprocedural-skin-care-regimen-for-ablative-resurfacing-100628507","NCT07462533","Assess Efficacy of a Nanodiamond Periprocedural Skin Care Regimen for Ablative Resurfacing","A Prospective, Randomized, Open-label Study Evaluating the Efficacy of a Nanodiamond Periprocedural Skin Care Regimen for Ablative Resurfacing","Inclusion Criteria:\n\n1. Males or females in good general health age 35-70 years of age.\n2. Subjects with score Moderate to Severe (Class II-III, Score 4-9) on the Fitzpatrick-Goldman Classification of Wrinkling and Degree of Elastosis Scale (Appendix E)\n3. Subjects with score Moderate to Severe facial photodamage as assessed by the Modified Griffth's Scale (Appendix F)\n4. Fitzpatrick skin types I-III.\n5. Must be willing to give and sign Informed Consent Form, Photography Release Form and HIPAA Form.\n6. The subject must be planning to undergo ablative CO2 and Er:YAG laser resurfacing to the face and willing to comply with study dosing and complete the entire course of the study.\n7. Subjects using any skin care products (per physician-investigator discretion) must discontinue use of these products 14 days before treatment and throughout the duration of the study. Subjects will only use the products they are instructed to use by the investigator.\n8. Male subjects with facial hair must be willing to shave the morning of the procedure\n9. Female patients will be either of non-childbearing potential defined as: Having no uterus or no menses for at least 12 months. Women of childbearing potential must agree to use an effective method of birth control during the study, such as:\n\n   1. Hormonal contraception - pill, injection, implant, patch, vaginal ring, Intrauterine device\n   2. Intrauterine coil\n   3. Bilateral tubal ligation\n   4. Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom)\n   5. Abstinence (If practicing abstinence must agree to use barrier method described above (4) if becomes sexually active).\n   6. Vasectomized partner (Must agree to use barrier method described above (4) if becomes sexually active with an Un-Vasectomized partner).\n   7. Negative urine pregnancy test results at Baseline prior to procedure (if applicable\n\nExclusion Criteria:\n\n1. Pregnant, planning to become pregnant during the course of the study, or breastfeeding.\n2. Prescence of an active bacterial, fungal, or viral infection in the treatment area.\n3. Significant history or current evidence of a medical, psychological or other condition that, in the investigator's opinion, would preclude enrollment into the study.\n4. Use of any topical products containing tretinoins or derivatives, alpha-hydroxy acids, salicylic acid, and vitamins C or E (includes derivatives thereof) on the face within 14 days prior to or during the study period, other than the study products.\n5. Receipt of a chemical peel, any systemic steroids, a non-ablative laser, ablative laser, microfocused ultrasound, light or radio frequency treatment, deep chemical peel, or dermabrasion on their face within 6 months prior to study enrollment.\n6. Receipt of a microdermabrasion (light or medium skin peel) treatment to the face within 30 days prior to enrollment and unwillingness to refrain from use for the duration of the study period.\n7. Excessive exposure to sunlight or artificial UV light (e.g.: use of tanning beds\u002Fbooths and\u002For sunbathing) or expectations of tanning during the time of the study or has used self-tanner within 7 days prior to enrollment.\n8. Prior treatment with a systemic retinoid within the past 3 months (e.g., Accutane®, Roche Dermatologics).\n9. History of keloids or hypertrophic scars.\n10. Known allergy to Valacyclovir or Fluconazole or sensitivities to benzocaine, lidocaine, tetracaine, PABA (para-amino benzoic acid), or other local anesthetics of the amide or ester family sedation medication.\n11. Presence of tattoo and\u002For scar in the treatment area that in the investigator's opinion would interfere with study assessments.\n12. History of or the presence of any skin condition\u002Fdisease that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis, seborrheic dermatitis) at the discretion of the physician-investigator\n13. Inability to comply with all study protocol restrictions and visits.\n14. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.\n15. History of non-compliance with clinical research protocols.","35 Years","70 Years",{"count":108,"type":22},8,[110],"PHASE2","The primary objective of this study is to evaluate the efficacy and tolerability of Pavise Extracellular Matrix Restore (ECMR), compared with standard acute post-operative care, when used as the primary occlusive treatment immediately following ablative CO₂ and Er:YAG facial laser resurfacing to support wound healing.",[28],[114,115,116,117],"face","rejuvenation","wrinkles","texture","2026-03-05",{"date":120,"type":33},"2026-03-10",{"date":122,"type":22},"2026-03-20",{"date":124,"type":22},"2026-08-30",{"name":126,"class":127},"Goldman, Butterwick, Fitzpatrick and Groff","OTHER",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":135,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":41},"100623622","a-study-to-characterize-human-skin-changes-from-biostimulator-treatments-via-non-invasive-imaging-100623622","NCT07399028","A Study to Characterize Human Skin Changes From Biostimulator Treatments Via Non-invasive Imaging","A Single-center, Open-label Study to Characterize Human Skin Changes From Biostimulator Treatments Via Non-invasive Imaging","Inclusion Criteria:\n\n* Adult subjects aged 45-65 years old\n* Females only\n* Subject with moderate-to-severe cheek wrinkles on the GCWS\n* Subject with intent to undergo correction of cheek wrinkles on both sides of the face\n* Subject who in the opinion of the Investigator would need 3 treatments for optimal clinical outcomes\n* Subject willing to be photographed at each visit.\n* Subjects willing to stop using current facial skincare products for the duration of the study.\n* Subject willing to replace the current facial skincare products with the provided facial skincare products, including cleanser, moisturizer and sunscreen, until study completion.\n* Ability to read, understand and give consent for participation in the study.\n* Agreement to adhere to the procedures and requirements of the study and to report to the site on the day(s) and at the time(s) scheduled for the assessments.\n\nExclusion Criteria:\n\n* Subjects with a history of allergy or hypersensitivity to any ingredient of the treatment products.\n* Previous tissue-augmenting therapy, contouring, or revitalization treatment in the face, except lips.\n* Previous treatment\u002Fprocedure in the face in the previous 6 months that, in the Investigator's opinion, would interfere with the study injections and\u002For study assessments or exposed the study subject to undue risk by study participation, or planning to undergo any of these procedures affecting the treatment area at any time during the study.\n* Subjects with any medical condition that, in the opinion of the Investigator, would make the subject unsuitable for inclusion.","FEMALE","45 Years","65 Years",{"count":139,"type":22},25,[25],"Adult subjects with moderate-to-severe cheek wrinkles will be treated with Sculptra for correction of fine lines and wrinkles in the cheek area.",[143,28,144],"Volume Deficiency in the Mid-Face","Photo-aged Skin","2026-02-02",{"date":147,"type":33},"2026-02-10",{"date":149,"type":33},"2025-10-21",{"date":151,"type":22},"2026-09",{"name":153,"class":40},"Galderma R&D",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":161,"maxAge":137,"enrollmentInfo":162,"targetDuration":4,"studyType":164,"phases":4,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":41},"100610230","ellacor-micro-coring-technology-in-fitzpatrick-skin-types-i-vi-including-patients-receiving-glucagon-like-peptide-1-receptor-agonists-100610230","NCT07224880","Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists","Safety and Outcomes of Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs): A Case Series","Inclusion Criteria:\n\n1. Male and female adult, between the ages of 30 and 65\n2. Fitzpatrick Skin Type I-VI\n3. Have moderate to severe wrinkles on the mid and lower face, according to Lemperle Wrinkle Severity Scale (LWSS), i.e. score 3, 4 or 5.\n4. Have moderate to extreme abdominal laxity according to Stokes Scale (i.e., score of 2-4 on a scale of 0-4).\n5. Willingness to sign Informed Consent Form\n\nExclusion Criteria:\n\n1. Pregnant women or nursing mothers\n2. Patients with dermatosis, open wounds, sores, or irritated skin in the treatment area\n3. Patients with allergy to stainless steel or to topical, oral, or injected medications or preparations that may be used during the procedure, such as petrolatum, lidocaine, bupivacaine, chlorhexidine, or povidone-iodine\n4. Patients with a history or presence of any clinically significant bleeding disorder\n5. Patients with dermatological or autoimmune conditions that may affect the treatment outcome; these may include, but are not limited to: actinic keratosis, raised nevi, rosacea, melasma, active acne, cutaneous papules\u002Fnodules, active inflammatory lesions, dermatitis, psoriasis, cellulitis, urticarial folliculitis, acute inflammatory phase of scleroderma, rheumatoid arthritis, eczema, psoriasis, allergic dermatitis, collagen disorders, or lupus\n6. Patients with systemic infections or acute local skin infections (as Hepatitis disorders type A, B, C, D, E or F or HIV infection)\n7. Patients who are on a high dose of anti-coagulants or blood-thinning substances, e.g., aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, heparin, acetylsalicylic acid during the previous fourteen (14) days\n8. Patients who are on courses of chemotherapy, high-dose corticosteroid use, or radiation in the treatment area\n9. Patients with have undergone plastic surgery of the face within the last twelve (12) months or have any facial surgical scars less than twelve (12) months old\n10. Patients who have undergone injections of dermal fillers, fat, or botulinum toxin, as well as any minimally invasive\u002Finvasive skin treatment in the treatment area during the previous six (6) months\n11. Patients with scars less than six (6) months old in the treatment area","30 Years",{"count":163,"type":22},10,"OBSERVATIONAL","The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared to the skin that wasn't treated including patients receiving GLP-1's, a class of medications that mimic a natural hormone to help control blood sugar and support weight loss. The study will also evaluate side effects that occur with this treatment, if any. Standardized 2D Imaging will be used to quantify reduction of wrinkle severity",[167,168,28],"glp1 Agonist","Gene Expression",[170,171,172],"ellacor","GLP-1","weight loss","2025-12-30",{"date":175,"type":33},"2025-12-31",{"date":177,"type":33},"2025-10-14",{"date":179,"type":22},"2026-02-28",{"name":181,"class":40},"Cytrellis Biosystems, Inc.",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":137,"enrollmentInfo":189,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":4},"100588948","restructuring-the-mandibular-angle-in-facial-aging-a-novel-tecnique-using-poly-l-lactic-acid-100588948","NCT06948045","RESTRUCTURING THE MANDIBULAR ANGLE IN FACIAL AGING: A NOVEL TECNIQUE USING POLY-L-LACTIC ACID","Restructuring the Mandibular Angle in Facial Aging: a Novel Tecnique Using Poly-L-Lactic Acid","Inclusion Criteria:\n\n1. Male or female individuals aged between 18 and 65 years of age.\n2. Immunocompetent individuals.\n3. Medical history and physical examination that, in the opinion of the investigator, do not prevent or contraindicate participation in the study or the use of the investigational product.\n4. Female research participants of childbearing potential with a negative UPT at baseline (Day 1). These participants must use a highly effective contraceptive method throughout the study: combined oral contraceptives (estrogen and progesterone) or implanted\u002Finjectable contraceptives (with a stable dose for at least 1 month prior to study entry), bilateral tubal ligation, hormonal intrauterine device (inserted at least 1 month before entering the study), strict abstinence (at least 1 month prior to study entry and agreeing to continue throughout the study duration), vasectomized partner (at least 3 months before study entry), or condom use.\n5. Women not of childbearing potential (e.g. postmenopausal with no menstrual bleeding for 1 year prior to study entry, hysterectomy, or bilateral oophorectomy).\n6. Research participants who are willing and able to comply with the duration and procedures required by the study protocol.\n7. Research participants who understand and sign the ICF and the ICF for image use authorization upon entering the study, before any investigational procedures are performed.\n\nExclusion Criteria:\n\n1. Participants unable to understand the research protocol and\u002For follow the study schedule.\n2. Pregnant or breastfeeding women, or those planning to become pregnant during the study period.\n3. History of treatment in the past 6 months or planning to undergo procedures with lasers, intense pulsed light, radiofrequency, microfocused ultrasound, or deep chemical peels.\n4. History of treatment with botulinum toxin on the face in the past 6 months or planning to undergo this procedure.\n5. History of treatment with hyaluronic acid-based or other non-permanent dermal fillers on the face in the past 12 months, or planning to undergo this procedure.\n6. History of treatment with collagen biostimulators on the face, such as poly-L-lactic acid (PLLA), calcium hydroxyapatite, or polycaprolactone, in the past 36 months, or planning to undergo this procedure.\n7. History of treatment with or planning to use permanent fillers on the face.\n8. Current use, use within the past 3 months, or planned use of collagen-based supplements.\n9. Any surgical procedure or other treatment previously performed that has affected the area to be assessed in this study.\n10. Active inflammation or infections in the facial region.\n11. Severe psychiatric disorders.\n12. Any other uncontrolled, chronic, or severe medical condition that, in the investigator's opinion, may interfere with the interpretation of the clinical study results or pose significant risk to the research participant.\n13. History of sensitivity to any component of the product used in the study.\n14. Vulnerable participants (such as those deprived of liberty), as defined in Section 1.61 of the International Conference on Harmonization (ICH) Guideline for Good Clinical Practice (GCP).\n15. History of poor treatment adherence or demonstrated lack of cooperation in adhering to the study protocol.\n16. Current participation in any other drug or device clinical study OR participation within 30 days prior to Day 1 or within an exclusion period of a previous clinical study.",{"count":190,"type":22},46,[25],"Skin laxity is a common complaint among patients seeking aesthetic dermatological interventions, affecting the facial contour, especially in the mandibular angle, due to bone aging and the loss of tissue support in the lower third of the face. Facelift surgery is an effective method to address this issue, but it is invasive and may impact the definition of the jawline. As an alternative, poly-L-lactic acid (PLLA) stimulates collagen production, improving facial contour in a minimally invasive manner. This study aims to evaluate the safety and effectiveness of a new, low-cost, and quick application technique using poly-L-lactic acid in the mandibular angle and anterior to the mandibular ligament. The proposed technique seeks to enhance facial contour, provide an additional lifting effect, and contribute to overall facial rejuvenation. This is a clinical, prospective, and interventional study, allowing the analysis of clinical outcomes in terms of efficacy and safety. Twenty volunteers aged between 18 and 65, of both genders, with no restrictions on the use of collagen bio-stimulators, will be recruited. After confirming inclusion and exclusion criteria, participants will sign the Informed Consent Form (ICF) and be eligible for the study. The first intervention will occur at visit 2 (day 1), the second intervention at visit 3 (day 30 ± 15), and the third intervention will be performed as indicated at visit 4 (day 60 ± 15). Final follow-up will take place at visit 5 (day 90 ± 15). Questionnaires will be applied and photographs taken at all visits. Injections will be administered with poly-L-lactic acid in the mandibular angle region and anterior to the mandibular ligament. The study will be funded by the Research Department of the Hexsel Dermatology Clinic, and the data collected will be used to prepare an article for publication.",[28,194],"Facial Aging",[196,81,197,198,199],"Restructuring the mandibular angle in facial aging: a new technique using poly-L-lactic acid (PLLA)","poly-L-lactic acid","mandibular angle","facial aging","2025-11-21",{"date":202,"type":33},"2025-11-26",{"date":204,"type":22},"2026-02-01",{"date":206,"type":22},"2027-02",{"name":208,"class":127},"Doris Hexsel",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":136,"maxAge":50,"enrollmentInfo":216,"targetDuration":4,"studyType":23,"phases":218,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":4},"100612538","safety-and-efficacy-of-2910-nm-fiber-laser-resurfacing-and-laser-coring-100612538","NCT07254884","Safety and Efficacy of 2910 nm Fiber Laser Resurfacing and Laser-Coring","Safety and Efficacy of 2910 nm Fiber Laser Resurfacing and Laser-Coring Treatment to Lift the Eyebrow, Submental Lax Tissue and Address Advanced Signs of Facial Aging","Inclusion Criteria:\n\n* Fitzpatrick skin type I-VI\n* Male or female\n* Subjects must be between 45 and 85 years of age\n* Subjects must have the ability to receive two and up to three full face and upper neck resurfacing laser treatments (pending PI discretion) with desire to lift facial lax skin, submental and\u002For to lift the eyebrow area and\u002For improve facial wrinkles appearance\n* Subjects must read, understand, and sign the Informed Consent Form\n* Subjects must be willing and able to comply with all follow-up visit requirements\n* Subjects must agree to refrain from using cosmeceutical agents or topical agents during the study, except as directed by study investigator\n* Subjects must be rated as (2) Moderate Sagging to (4) Very Severe Sagging based on the Merz Scale: Jawline at Rest\n* Subject identified as an appropriate candidate for study treatment based on principal investigator's opinion\n* Subjects of childbearing potential have been on an acceptable form of contraception for 30 days prior to enrollment and agree to continue using throughout the course of the study\n\nExclusion Criteria:\n\n* Subjects must not have active localized or systemic infections\n* Subjects must not have a compromised ability for wound healing, such as: malnutrition, steroid use, history of collagen vascular disease (e.g., lupus, scleroderma, history of keloid scar formation), atopic dermatitis or immunologic abnormalities such as vitiligo\n* Subjects must not be current smoker or have significant history of smoking\n* Subjects must not have had treatments with systemic steroids or systemic retinoids in the 4-months prior to enrollment\n* Subjects must not have had treatments with 5FU, diclofenac, imiquimod or PDT within 1-month prior to enrollment\n* Subjects must not have severe or cystic facial acne; currently taking Accutane or have taken Accutane within the last 1-month\n* Subjects must not have a known allergy to lidocaine or epinephrine, topical or injectable products containing lidocaine or any numbing medications\n* Subjects must not have had previous surgery and\u002For fat transfer in the treatment area within the last 6-months\n* Subject must not have had injectable soft tissue fillers within the last 12 months in the treatment area\n* Subject must not have had Poly-L-Lactic acid (PLLA) fillers within the last 2 years in the treatment area\n* Subject must not have had permanent filler i.e., Polymethylmethacrylate (PMMA) in the treatment area\n* Subjects must not have had neurotoxins within the last 4-months in the treatment area\n* Subject must not have a personal history of any facial threads i.e., PDO (Polydioxanone), PLLA (Polylactic acid), PCL (Polycaprolactone) in the treatment area within the last 12-months\n* Subject must not have had a pulse dye or vascular laser, non-ablative laser, microneedling or RF microneedling treatments in the treatment area within the last 3-months\n* Subject must not have had an ultrasound treatment such as HIFU, monopolar RF energy-based devices, ablative laser treatments in the treatment area within the last 6-months\n* Subjects must not have a personal history of malignant melanoma, keloid scars, generalized psoriasis or systemic diseases that would preclude the use of topical anesthesia\n* Subject must not have active sunburn or excessively tanned skin\n* Subjects must not be pregnant or planning to become pregnant, have given birth less than 3 months ago, and\u002For breastfeeding during the study",{"count":217,"type":22},40,[25],"The primary objective of this clinical trial is to evaluate the safety and effectiveness of the 2,910 nm mid-infrared erbium-doped fluoride fiber glass laser (UltraClear, Acclaro Medical) for non-invasive dermatological aesthetic treatment of three facial regions: eyebrow lift (Region 1), submental tissue lift (Region 2), and improvement of rhytids and skin laxity in the cheeks, midface, and jawline (Region 3).",[221,28],"Rhytids",[223,224,225,221],"Eyebrow Lift","Submental Tissue Lift","Wrinkles","2025-11-20",{"date":228,"type":33},"2025-11-28",{"date":230,"type":22},"2025-11",{"date":232,"type":22},"2026-11",{"name":234,"class":40},"FA Corporation",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":242,"targetDuration":4,"studyType":23,"phases":244,"briefSummary":245,"conditions":246,"keywords":252,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":41},"100589789","effects-of-quantum-probe-for-skin-rejuvenation-and-subdermal-retraction-in-patients-undergoing-high-definition-liposculpture-100589789","NCT06958978","Effects of QUANTUM Probe for Skin Rejuvenation and Subdermal Retraction in Patients Undergoing High-Definition Liposculpture","Quantum001","Inclusion Criteria:\n\n* Patients undergoing body contouring procedures (liposuction or liposculpture), either individually or combined with a maximum of two other major aesthetic procedures involving face, breast, or dermolipectomy.\n* Healthy patients without underlying comorbidities (classified as ASA≤II)\n\nExclusion Criteria:\n\n* Pregnant patients, patients planning to get pregnant, or in breastfeeding stage\n* Past medical history of any collagen disease or autoimmune conditions, including lupus, scleroderma, connective tissue disorders, rheumatoid arthritis, or multiple sclerosis.\n* Past medical history of skin disease including active skin infections, dermatitis, or history of keloid formation.\n* Patient with any metal implants or pacemakers\n* BMI ≥ 32 kg\u002Fm2.",{"count":243,"type":22},80,[25],"This prospective study aims to evaluate the safety and effectiveness of Quantum, a fully internal bipolar radiofrequency probe, for the treatment of prominent skin laxity, providing patients with a more toned and youthful appearance, in patients undergoing High-Definition (HD) Liposculpture.\n\nThe main questions this study seeks to answer are:\n\n* Does Quantum reduce skin laxity in patients undergoing HD Liposculpture?\n* Is the effectiveness in skin laxity reduction influenced by demographical factors, including age, gender, and phototype?\n\nThe participants will be adult patients (between 18-60 years) undergoing HD Liposculpture, with any measurable degree of skin laxity. The participants can not be pregnant, have history of scaring\u002Fhealing problems, autoimmune diseases, severe dermatological conditions, have metal implants, be obese, or have important comorbidities.",[28,247,248,249,250,251],"Skin Tightening","Body Contouring Surgery","Skin Elasticity","Skin Firmness","Liposuction",[253,254,255,256,251,257,258],"Quantum","Quantum RF","Elastometer","Body contouring","Liposculpture","High Definition Liposculpture","2025-04-27",{"date":261,"type":33},"2025-05-06",{"date":263,"type":33},"2024-02-01",{"date":265,"type":22},"2026-06",{"name":267,"class":127},"Total Definer Research Group",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":49,"sex":17,"minAge":274,"maxAge":19,"enrollmentInfo":275,"targetDuration":276,"studyType":164,"phases":4,"briefSummary":277,"conditions":278,"keywords":280,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":41},"100587183","quantified-evaluation-of-noninvasive-system-delivering-microwave-energy-for-unwanted-fat-reduction-and-skin-tightening-in-asians-100587183","NCT06925074","Quantified Evaluation of Noninvasive System Delivering Microwave Energy for Unwanted Fat Reduction and Skin Tightening in Asians.","Inclusion Criteria:\n\n* Men and women aged between 20 and 60.\n* Subjects who are capable of understanding and comply with the study procedures, instructions, and visit schedule.\n* Subjects who voluntarily decide to participate in the entire course of the trial and provide written consent in the Informed Consent Form.\n\nExclusion Criteria:\n\n* Subjects with autoimmune diseases\u002Freceived immunotherapy and subjects with diabetes mellitus.\n* Subjects with a history of a hypertrophic scar.\n* Pregnant or breastfeeding women.\n* Subjects with untreated epilepsy or underlying porphyria.\n* When there is an active disease (such as inflammation, infection or tumors) in or near the intended treatment site.\n* Treatment procedure (e.g., bioresorbable fillers, laser\u002Flight therapies, botulinum toxin A injections, facial lift, facial peels, excisional facial surgery, dermal photorejuvenation, oral or maxillofacial surgery, etc.) that may interfere with the treatment area or evaluation within 6 months before screening as determined by the Principal Investigator.\n* The subject who received soft tissue augmentation at the treatment site at any time before screening as determined by the Principal Investigator.\n* Subjects with a scar or skin lesion at the treatment site that may interfere with the judgment of the treatment effect.\n* Subjects who participated in another clinical trial within 60 days before screening or plan to participate in another investigation during this study.\n* Subjects who plan to receive other wrinkle improvement treatments in the face during this trial.\n* Subjects who are otherwise determined by the investigator as ineligible for this study.","20 Years",{"count":21,"type":22},"3 Months","The goal of this observational study is to evaluate the effectiveness and safety of microwave-assisted heating technology in facial fat reduction and skin tightening in Asians.\n\nThe main questions it aims to answer are:\n\n1. How effective is the microwave-based system in reducing fat and tightening Skin?\n2. What objective methods can be used to measure treatment outcomes?\n3. What are the optimal treatment parameters for maximum efficacy?\n4. What are the safety and side effects associated with the treatment?\n5. How long-lasting are the results?\n\nParticipants will go through three treatment sessions using the \"DEKA\" ONDA Microwave treatment system, with each session lasting 12 minutes.",[194,28,279],"Cheek Wrinkles",[281,282,283,284,285],"3D imaging","Skin laxity","Microwaves","Fat reduction","Facial aging","2025-04-06",{"date":288,"type":33},"2025-04-13",{"date":290,"type":22},"2025-05",{"date":292,"type":22},"2026-04",{"name":294,"class":127},"Chang Chang Cheng",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":49,"sex":135,"minAge":105,"maxAge":72,"enrollmentInfo":303,"targetDuration":4,"studyType":23,"phases":305,"briefSummary":306,"conditions":307,"keywords":310,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":41},"100562440","benefit-of-bovine-or-marine-collagen-vs-placebo-on-skin-hair-nails-and-whole-body-health-in-healthy-adults-100562440","NCT06603194","Benefit of Bovine or Marine Collagen Vs. Placebo on Skin, Hair, Nails and Whole Body Health in Healthy Adults","BECOME Study: Comparative Efficacy of Bovine and Marine Collagen Versus Placebo on Skin, Hair, Nails and Whole Body Health Markers","BECOME","Inclusion Criteria:\n\nFemales aged 35-55 years. Participants must be comfortable with bovine or marine collagen (non-vegan\u002Fvegetarian).\n\nMust provide informed consent and be willing to comply with study requirements.\n\nExclusion Criteria:\n\nPregnant or breastfeeding women. History of chronic skin conditions (e.g., eczema, psoriasis) that might interfere with study outcomes.\n\nAny active skin infections or severe acne. Currently taking collagen supplements or have taken them within the last 6 months.\n\nUse of medications or topical agents that can affect skin, hair, nails, or gastrointestinal health (e.g., corticosteroids, retinoids).\n\nExcessive alcohol consumption or current smokers. Regular use of sunbeds. Recent cosmetic procedures (e.g., Botox, fillers, chemical peels, laser treatments) on skin, hair, or nails within the last 3 months.\n\nAny condition or situation that, in the opinion of the investigator, may interfere with the participant's ability to comply with the study requirements or give informed consent.\n\nPoor adherence to previous study protocols",{"count":304,"type":22},90,[25],"The BECOME Study (Bovine and Marine Collagen Efficacy for Skin, Hair, Nails and Whole Body Health Markers Evaluation) is a randomized controlled trial designed to compare the effects of bovine and marine collagen supplements versus a placebo on skin, hair, nails and whole body health markers. The trial aims to determine the most efficacious collagen source for improving health outcomes and to establish if both types of collagen are equally effective. Participants will be assessed on various health parameters, including skin elasticity, joint health, digestive health, and overall well-being, over a specified period.",[28,308,309],"Hair Thinning","Nails",[311,312,313],"Collagen","Skin health","Skin density","2024-09-16",{"date":316,"type":33},"2024-09-19",{"date":318,"type":33},"2024-08-26",{"date":320,"type":22},"2024-12-20",{"name":322,"class":40},"Ancient + Brave",{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":49,"sex":17,"minAge":330,"maxAge":331,"enrollmentInfo":332,"targetDuration":4,"studyType":23,"phases":334,"briefSummary":335,"conditions":336,"keywords":338,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":41},"100554627","association-of-leucocyte-telomere-length-with-dpas-score-in-skin-aging-100554627","NCT06501547","Association of Leucocyte Telomere Length With DPAS Score in Skin Aging","Association of Leucocyte Telomere Length With Clinical Examination and Dermoscopic Photoaging Scale (DPAS) Score in Skin Aging: a Pilot Study","Inclusion Criteria:\n\n* Female and Male (age 29-31 years old and 59-61 years old\n* signs of aging\n\nExclusion Criteria:\n\n* pregnant or breastfeeding\n* have disease or genetic problem","29 Years","61 Years",{"count":333,"type":22},20,[25],"The goal is to know the profile of photoaging based on clinical examination, Dermoscopic Photoaging Scale and leucocyte telomere length\n\nThe main questions of Research are:\n\n* what is the profile of photoaging based on clinical examination results in skin aging\n* what is the profile of photoaging based on DPAS Score in skin aging\n* what is the profile of leucocyte telomere length in skin aging\n\nParticipants are female and male with the age of 29-31 years old and 59-61 years old. They will be examined by dermatovenereologist and will be photographed in 5 positions, they will get dermocopy on forehead, right cheek , left cheek, and chin, and their blood will be drawn about 10 mL in order to get the profile of leucocyte telomere length",[337,28],"Aging",[339,340,341,342,343,344,345,346],"Dermoscopy","Dermoscopic photoaging scale (DPAS)","Glogau scale","Leucocyte telomere length (LTL)","Photoaging","Skin aging","Telomere","Ultraviolet (UV)","2024-07-09",{"date":349,"type":33},"2024-07-15",{"date":351,"type":33},"2023-10-01",{"date":353,"type":22},"2024-09-01",{"name":355,"class":127},"Dr.dr.Irma Bernadette, SpKK (K)"]